Core Viewpoint - Evoke Pharma, Inc. is expanding access to its GIMOTI nasal spray for diabetic gastroparesis through strategic partnerships with Omnicell and Brentwood Pharmacy, aiming to enhance patient care and streamline access to treatment [1][2][3]. Company Overview - Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing treatments for gastrointestinal disorders, particularly GIMOTI, a nasal spray formulation of metoclopramide for adults with acute and recurrent diabetic gastroparesis [4][5]. Strategic Partnerships - The partnership with Omnicell is expected to nearly double the number of specialty pharmacies that can access GIMOTI, aligning with large gastroenterology practices like Gastro Health, which operates in 7 states and has 150 locations [2][3]. - The agreement with Brentwood Pharmacy, affiliated with OneGI, enhances access to GIMOTI across multiple states, including Tennessee, Kentucky, Ohio, and Mississippi, and supports rapid delivery and additional insurance plan access for patients [3][4]. Market Context - Diabetic gastroparesis is a significant gastrointestinal disorder affecting millions globally, characterized by delayed gastric emptying, which can complicate the absorption of orally administered medications [5]. - GIMOTI is the only FDA-approved treatment for diabetic gastroparesis in the United States, previously available only in oral and injectable forms [5]. Industry Collaboration - EVERSANA, a provider of global commercial services to the life sciences industry, is supporting Evoke in its strategy to improve patient access and streamline the integration with specialty pharmacies [1][12]. - Gastro Health and OneGI are key players in the gastroenterology space, providing extensive networks of physicians and specialized care, which Evoke aims to leverage through its partnerships [13][14].

Core Viewpoint - Processa Pharmaceuticals has entered into a binding term sheet with Intact Therapeutics for the exclusive option to license PCS12852, a 5-HT4 receptor agonist aimed at treating gastroparesis and other gastrointestinal motility disorders [1][3]. Financial Terms - Processa is set to receive a $2.5 million option exercise fee, up to $20 million in development and regulatory milestone payments, and over $432.5 million in commercial milestone payments based on net product sales [2][8]. - Intact will pay Processa a double-digit royalty on worldwide net sales of licensed products, excluding South Korea, and provide an equity stake of 3.5% in Intact upon closing [2][8]. Clinical Significance - PCS12852 has shown a favorable safety and efficacy profile in clinical studies, particularly in a Phase 2a trial for diabetic gastroparesis, a condition with limited treatment options [3][4]. - The drug is designed to restore normal gastric emptying without the cardiovascular and central nervous system side effects associated with older agents in this class [3]. Strategic Partnership - The partnership is expected to unlock the value of Processa's non-oncology assets while focusing on developing next-generation cancer therapies [3]. - Intact Therapeutics aims to address significant unmet clinical needs in gastrointestinal diseases, enhancing patient quality of life through innovative therapies [3][5]. Company Background - Intact Therapeutics is a clinical-stage biopharmaceutical company focused on next-generation therapies for gastrointestinal diseases, leveraging proprietary thermal hydrogel technology [5]. - Processa Pharmaceuticals specializes in developing next-generation cancer drugs with improved safety and efficacy, modifying existing FDA-approved oncology therapies [7].